Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

194.18USD
16 Nov 2018
Change (% chg)

$1.73 (+0.90%)
Prev Close
$192.45
Open
$192.36
Day's High
$195.24
Day's Low
$191.71
Volume
1,537,639
Avg. Vol
1,130,745
52-wk High
$210.18
52-wk Low
$163.31

Latest Key Developments (Source: Significant Developments)

Amgen Sets Quarterly Dividend Of $1.32/Share
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Amgen Inc ::SETS QUARTERLY DIVIDEND OF $1.32PER SHARE.  Full Article

FDA Approves KYPROLIS Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Amgen Inc ::FDA APPROVES KYPROLIS® (CARFILZOMIB) ONCE-WEEKLY 70 MG/M2 IN COMBINATION WITH DEXAMETHASONE (KD70) FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.AMGEN INC - APPLICATION REVIEWED AND APPROVED UNDER FDA'S REAL-TIME ONCOLOGY REVIEW AND ASSESSMENT AID PILOT PROGRAMS.AMGEN INC - APPROVAL OF A MORE CONVENIENT ONCE-WEEKLY KD70 REGIMEN BASED ON DATA FROM PHASE 3 HEAD-TO-HEAD A.R.R.O.W. STUDY.AMGEN INC - OVERALL SAFETY PROFILES OF TWO ARMS IN A.R.R.O.W. WERE COMPARABLE, WITH NO NEW SAFETY RISKS IDENTIFIED IN ONCE-WEEKLY ARM.AMGEN INC - KYPROLIS IS NOT APPROVED FOR TWICE-WEEKLY 27 MG/M(2) ADMINISTRATION IN COMBINATION WITH DEXAMETHASONE ALONE..AMGEN INC - FDA APPROVED SNDA TO EXPAND PRESCRIBING INFORMATION FOR KYPROLIS TO INCLUDE A ONCE-WEEKLY DOSING OPTION IN COMBINATION WITH DEXAMETHASONE.  Full Article

Astrazeneca Says Tezepelumab Gets FDA Breakthrough Therapy Status
Friday, 7 Sep 2018 

Sept 7 (Reuters) - AstraZeneca Plc ::TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION.TEZEPELUMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA.ASTRAZENECA'S FIRST BREAKTHROUGH THERAPY DESIGNATION FOR A RESPIRATORY MEDICINE.  Full Article

Tezepelumab Granted Breakthrough Therapy Designation By US FDA
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Amgen Inc ::TEZEPELUMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA FOR THE TREATMENT OF PATIENTS WITH SEVERE ASTHMA WITHOUT AN EOSINOPHILIC PHENOTYPE.TEZEPELUMAB IS CURRENTLY IN DEVELOPMENT IN PHASE 3 PATHFINDER CLINICAL TRIAL PROGRAM.  Full Article

Amegen - European Commission Approves Blincyto
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Amgen Inc ::EUROPEAN COMMISSION APPROVES BLINCYTO® (BLINATUMOMAB) FOR USE IN PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA.AMGEN - APPROVAL IS BASED ON RESULTS FROM PHASE 1/2 '205 STUDY,OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL WHICH EVALUATED EFFICACY & SAFETY OF BLINCYTO.  Full Article

Amgen Submits Supplemental New Drug Application For Kyprolis
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Amgen Inc ::AMGEN SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR KYPROLIS® (CARFILZOMIB) ONCE-WEEKLY 70 MG/M2 IN COMBINATION WITH DEXAMETHASONE.AMGEN INC - FDA REVIEWING APPLICATION UNDER ONCOLOGY CENTER OF EXCELLENCE REAL-TIME ONCOLOGY REVIEW AND ASSESSMENT AID PILOT PROGRAMS.  Full Article

Arrowhead Pharmaceuticals Earns $10 Mln Milestone Payment From Amgen
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS SAYS EARNED $10 MILLION MILESTONE PAYMENT FROM AMGEN FOLLOWING ADMINISTRATION OF FIRST DOSE OF AMG 890.  Full Article

Amgen Sets Quarterly Dividend Of $1.32/Share
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 2018 THIRD QUARTER DIVIDEND.SETS QUARTERLY DIVIDEND OF $1.32PER SHARE.  Full Article

Amgen Reports Qtrly Adjusted Earnings Per Share $3.83
Thursday, 26 Jul 2018 

July 26 (Reuters) - Amgen Inc ::AMGEN QTRLY EARNINGS PER SHARE $3.48; QTRLY ADJUSTED EARNINGS PER SHARE $3.83; QTRLY REVENUE $6.06 BILLION, UP 4 PERCENT.AMGEN SEES 2018 EARNINGS PER SHARE $11.83 - $12.62; SEES 2018 ADJUSTED EARNINGS PER SHARE $13.30 - $14.00; SEES 2018 REVENUE $22.5 BILLION - $23.2 BILLION.AMGEN SEES 2018 CAPEX TO BE ABOUT $750 MILLION.Q2 EARNINGS PER SHARE VIEW $3.54, REVENUE VIEW $5.73 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $13.75, REVENUE VIEW $22.59 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amgen, UCB Resubmit Biologics License Application For Evenity To U.S. FDA
Friday, 13 Jul 2018 

July 13 (Reuters) - AMGEN INC ::AMGEN AND UCB RESUBMIT BIOLOGICS LICENSE APPLICATION (BLA) FOR EVENITY™ (ROMOSOZUMAB) TO THE US FDA.  Full Article

Express Scripts offers new formulary for lower list-price drugs

Nov 13 Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled.